Supreme Court order leaves access to abortion pill unchanged

Key Points:

• The Supreme Court has temporarily preserved access to the abortion drug mifepristone by rejecting lower-court restrictions that required in-person doctor visits, allowing women to continue obtaining the drug via pharmacies or mail while a lawsuit proceeds.
• The case originates from Louisiana's challenge to the FDA's rules on mifepristone prescribing, arguing the policy undermines the state's abortion ban and raises safety concerns, although the FDA and medical experts maintain the drug is safe and effective.
• Justices Clarence Thomas and Samuel Alito dissented, criticizing the drug manufacturers and those mailing the pills, citing legal and moral objections, including references to the Comstock Act, a 19th-century law banning mailing abortion-related substances.
• The ruling maintains the status quo amid ongoing political and legal battles over abortion access following the overturning of Roe v. Wade, with abortion-rights advocates relieved but cautious and anti-abortion groups expressing disappointment and intent to continue litigation.
• The FDA's role and regulatory decisions on mifepristone remain under scrutiny, with recent political pressures including the resignation of FDA Commissioner Marty Makary, and the Trump administration's silence on the case reflecting the complex political dynamics surrounding abortion policy.